The University of Chicago Header Logo

Connection

Matthew Baggott to Humans

Back to Details
This is a "connection" page, showing publications Matthew Baggott has written about Humans.
Matthew Baggott
Connection Strength
0.206
Humans
  1. Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. J Psychoactive Drugs. 2019 Apr-Jun; 51(2):108-117.
    View in: PubMed
    Score: 0.023
  2. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol. 2016 Apr; 30(4):378-87.
    View in: PubMed
    Score: 0.018
  3. Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol. 2015 Jun; 29(6):669-77.
    View in: PubMed
    Score: 0.017
  4. Psychopharmacology of theobromine in healthy volunteers. Psychopharmacology (Berl). 2013 Jul; 228(1):109-18.
    View in: PubMed
    Score: 0.015
  5. Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One. 2010 Dec 02; 5(12):e14074.
    View in: PubMed
    Score: 0.013
  6. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend. 2011 Mar 01; 114(1):61-7.
    View in: PubMed
    Score: 0.013
  7. Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend. 2010 Oct 01; 111(3):250-6.
    View in: PubMed
    Score: 0.013
  8. Role of endocannabinoids in 5-HT2 receptor-mediated effects. J Neurophysiol. 2009 Jan; 101(1):5-7.
    View in: PubMed
    Score: 0.011
  9. Preventing problems in Ecstasy users: reduce use to reduce harm. J Psychoactive Drugs. 2002 Apr-Jun; 34(2):145-62.
    View in: PubMed
    Score: 0.007
  10. Caveat emptor: editors beware. Neuropsychopharmacology. 2001 Apr; 24(4):461-3.
    View in: PubMed
    Score: 0.007
  11. Chemical analysis of ecstasy pills. JAMA. 2000 Nov 01; 284(17):2190.
    View in: PubMed
    Score: 0.006
  12. Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing. Neuropsychopharmacology. 2020 04; 45(5):823-832.
    View in: PubMed
    Score: 0.006
  13. More about parkinsonism after taking ecstasy. N Engl J Med. 1999 Oct 28; 341(18):1400-1.
    View in: PubMed
    Score: 0.006
  14. The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? J Psychopharmacol. 2016 12; 30(12):1248-1258.
    View in: PubMed
    Score: 0.005
  15. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. 1996 Jul; 60(1):105-14.
    View in: PubMed
    Score: 0.005
  16. MDMA effects consistent across laboratories. Psychopharmacology (Berl). 2014 Oct; 231(19):3899-905.
    View in: PubMed
    Score: 0.004
  17. Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention. Exp Clin Psychopharmacol. 2013 Dec; 21(6):475-81.
    View in: PubMed
    Score: 0.004
  18. Ketamine is associated with lower urinary tract signs and symptoms. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):189-94.
    View in: PubMed
    Score: 0.004
  19. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol Ther. 2011 Jul; 90(1):179-83.
    View in: PubMed
    Score: 0.003
  20. A method to quantify illicit intake of drugs from urine: methamphetamine. J Pharmacol Exp Ther. 2011 Jul; 338(1):31-6.
    View in: PubMed
    Score: 0.003
  21. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011 Feb; 89(2):276-82.
    View in: PubMed
    Score: 0.003
  22. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl). 2011 Apr; 214(4):933-9.
    View in: PubMed
    Score: 0.003
  23. Efficacy, safety, and ethics of cosmetic neurology far from settled. Clin Pharmacol Ther. 2010 Oct; 88(4):461-3.
    View in: PubMed
    Score: 0.003
  24. An examination of drug craving over time in abstinent methamphetamine users. Am J Addict. 2010 Nov-Dec; 19(6):510-4.
    View in: PubMed
    Score: 0.003
  25. Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Ther Drug Monit. 2010 Aug; 32(4):504-7.
    View in: PubMed
    Score: 0.003
  26. The effects of inhaled L-methamphetamine on athletic performance while riding a stationary bike: a randomised placebo-controlled trial. Br J Sports Med. 2009 Oct; 43(11):832-5.
    View in: PubMed
    Score: 0.003
  27. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002 Aug; 162(4):396-405.
    View in: PubMed
    Score: 0.002
  28. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000 Dec 19; 133(12):969-73.
    View in: PubMed
    Score: 0.002
  29. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl). 1999 Jan; 141(1):37-46.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.